Preventing recurrent violent injury has always been an important component of public health approach to interpersonal violence. However, prior studies have done very little to highlight the true incidence of recurrent violent injury.
Preventing recurrent violent injury has always been an important component of public health approach to interpersonal violence. It has also been the prime focus of violence intervention programs. However, prior studies have done very little to highlight the true incidence of recurrent violent injury.
New research on recurrent violent injuries, its costs, and risk factors found that approximately 1 in 9 people sent to emergency rooms (ERs) for violent injuries in 2010 ended up being violently injured again within 2 years. The study was conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania and the findings are published in the American Journal of Emergency Medicine.
“While violence prevention programs in trauma centers have been shown to be effective, recurrent violent injury is still very common and very costly,” lead author Elinore Kaufman, MD, a resident in General Surgery at New York-Presbyterian/Weill Cornell Medical Center in New York, said in a statement. “We need to be doing more to make sure every patient has the resources they need to stay safe.”
Interpersonal violence led to more than 16,000 deaths, 140,000 hospitalizations, and 1.6 million ER visits in 2010, according to CDC. The medical costs for treating and preventing such incidences was an estimated $8.5 billion. While hospitals have focused on intervention programs to prevent recurrences among victims, the new research establishes more opportunities for intervention based on a statewide analysis.
Study Findings
The authors examined ER-reported injuries from interpersonal violence for Florida. All visits during 2010 and recurrent visits within 2 years were recorded. It was found that out of approximately 54,000 patients admitted to ERs for violent injuries in 2010, 11% returned with a new violent injury at least once within the next 2 years. At least 20% of these patients had 2 or more recurrences, with many injuries classifying as “severe.” These initial and recurrent ER visits amounted to a whopping $596 million in medical charges.
Other findings included:
Understanding the Risk Factors
Recurrent violent injury is a common and costly phenomenon. For effective violence prevention programs, understanding the risk factors could be the key.
Risk factors for recurrent violent injury included homelessness, residence in low income neighborhoods, and history of mental illness or alcohol abuse. Low income, homelessness, Medicaid or uninsurance, and black race were associated with increased odds of recurrence.
“These findings can serve as a baseline for interventions aimed at reducing recurrence,” Kaufman said. “Our findings also highlight the potential for housing stability, behavioral health and substance abuse programs to break cycles of violence.”
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More